Literature DB >> 30661071

Sentinel Lymph Node Biopsy in the Treatment of Endometrial Cancer: Why We Fail? Results of a Prospective Multicenter Study on the Factors Associated with Failure of Node Mapping with Indocyanine Green.

Manuel Maria Ianieri1,2, Andrea Puppo3, Antonia Novelli3,4, Federica Campolo5, Tommaso Staniscia6, Giuseppe Di Martino6, Elisa Piovano3, Francesco Bruni7, Giovanni Roviglione7, Daniele Mautone7, Marcello Ceccaroni7.   

Abstract

BACKGROUND: The sentinel lymph node (SLN) mapping for endometrial cancer staging is gaining wide diffusion, but there is no definitive evidence on the factors associated with the failure of mapping.
OBJECTIVES: To analyze the factors associated with the possible failure of bilateral SLN mapping with indocyanine green (ICG).
METHODS: A prospective observational study without control on 110 patients with endometrial cancer apparently confined to the uterus, underwent laparoscopic surgical staging with SLN mapping with ICG.
RESULTS: Possible risk factors associated with bilateral mapping failure were analyzed, and a multivariate analysis was performed. The bilateral detection rate for SLNs mapping was 72.7%, whereas at least one SLN was detected in 79.1% of patients. No SLNs were identified in 6.3%. None of the patients or features related to tumor were associated with a risk of failure of the method. The only factor analyzed that was significantly associated with the success of bilateral mapping was the surgeon (p = 0.003).
CONCLUSIONS: Neither obesity nor the presence of lymph node metastases was associated with mapping failure. However, there remains a need for further studies to understand all the mechanisms linked to the unsuccessful method results and to reduce the use of systematic lymphadenectomy in the case of mapping failure.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Endometrial cancer; Mapping; Risk failure; Sentinel lymph node

Mesh:

Substances:

Year:  2019        PMID: 30661071     DOI: 10.1159/000496699

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  3 in total

1.  The Feasibility of Sentinel Lymph-Node, Mapped with Indocyanine Green, Biopsy in Endometrial Cancer Patients: A Prospective Study.

Authors:  Migle Gedgaudaite; Arturas Sukovas; Saulius Paskauskas; Arnoldas Bartusevicius; Vaida Atstupenaite; Eimantas Svedas; Joana Celiesiute; Arvydas Cizauskas; Daiva Vaitkiene; Adrius Gaurilcikas
Journal:  Medicina (Kaunas)       Date:  2022-05-26       Impact factor: 2.948

2.  Sentinel lymph node mapping in high-risk endometrial cancer: a systematic review and meta-analysis.

Authors:  Qiang Ji; Xiuying Wang; Jiyong Jiang; Liyan Chen
Journal:  Gland Surg       Date:  2020-12

3.  Sentinel lymph node biopsy in high-risk endometrial cancer: performance, outcomes, and future avenues.

Authors:  Yoo-Na Kim; Young Tae Kim
Journal:  Obstet Gynecol Sci       Date:  2022-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.